Kaya17, Inc

Kaya17, Inc. has developed a novel platform for rapid diagnostic Point of Care testing, enabling a breakthrough in delivering accuracy and speed at a low cost. The company’s new Vertical Flow Filter method and lightweight, portable reader can be set up at any site for quick results. A complete test platform is provided, easily usable by anyone at a Point of Care site, and includes a complete patient data management solution that can report results to a phone app or to institutional, healthcare or government databases. The diagnostic platform can perform infectious diseases testing, allergy testing, cancer diagnosis, cardiovascular tests and others. The company’s first product is a CE Mark approved,15 min saliva-based antigen test for Covid-19 that has shown a remarkable 98% specificity and sensitivity in a randomized, blinded clinical trial.